1. Field of the Invention
The present invention relates to medical devices, and more particularly, to endotracheal devices, such as endotracheal tubes and cuffs.
2. Description of the Related Art
This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and/or claimed below. This discussion is believed to be helpful in providing the reader with background information to facilitate a better understanding of the various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.
In the course of treating a patient, a tube or other medical device may be used to control the flow of air, food, fluids, or other substances into the patient. For example, medical devices such as tracheal tubes may be used to control the flow of one or more substances into or out of a patient. In many instances it is desirable to provide a seal between the outside of the tube or device and the interior of the passage in which the tube or device is inserted. In this way, substances can only flow through the passage via the tube or other medical device, allowing a medical practitioner to maintain control over the type and amount of substances flowing into and out of the patient.
For example, tracheal tubes may be used to control the flow of air or other gases through a patient's trachea. Such tracheal tubes may include endotracheal (ET) tubes, tracheotomy tubes, or transtracheal tubes. To seal these types of tracheal tubes, an inflatable cuff may be associated with these tubes. When inflated, the cuff generally expands into the surrounding trachea to seal the tracheal passage.
However, to fit a range of trachea anatomies with a given size of tracheal tube, cuff diameters are usually about one and a half times the diameter of the average trachea. Therefore, when inserted in an average-sized trachea, such a cuff is unable to fully expand and will fold in on itself within the trachea. These folds may serve as leak paths that allow microbe laden secretions to flow past the cuff and enter the lung.
Certain aspects commensurate in scope with the originally claimed invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be set forth below.
There is provided an inflatable balloon cuff that includes a proximal opening and a distal opening in a wall of the balloon cuff; and a plurality of annular grooves and annular ridges substantially orthogonal to an imaginary axis connecting the proximal opening and the distal opening of the inflated balloon cuff., wherein the grooves are spaced 1 mm-4 mm apart.
There is also provided a method of manufacturing an inflatable balloon cuff that includes providing a balloon cuff wall with a proximal opening and a distal opening; and providing a plurality of annular grooves and annular ridges in the balloon cuff substantially orthogonal to an imaginary axis connecting the proximal opening and the distal opening of the inflated balloon cuff, wherein the grooves are spaced 1 mm-4 mm apart.
There is also provided an inflatable balloon cuff that includes a proximal opening and a distal opening in a wall of the balloon cuff; and an annular groove nonorthogonal to an imaginary axis connecting the proximal opening and the distal opening of the inflated balloon cuff.
There is also provided a method of manufacturing an inflatable balloon cuff comprising: providing a balloon cuff wall with a proximal opening and a distal opening; and providing an annular groove in the balloon cuff nonorthogonal to an imaginary axis connecting the proximal opening and the distal opening of the inflated balloon cuff.
There is also provided an inflatable balloon cuff that includes: a proximal opening and a distal opening in a wall of the balloon cuff; and a plurality of annular grooves and annular ridges substantially orthogonal to an imaginary axis connecting the proximal opening and the distal opening of the inflated balloon cuff, wherein at least a portion of the balloon cuff is less than 60 microns in thickness.
There is also provided an inflatable balloon cuff that includes: a proximal opening and a distal opening in a wall of the balloon cuff; and a plurality of annular grooves and annular ridges substantially orthogonal to an imaginary axis connecting the proximal opening and the distal opening of the inflated balloon cuff, wherein the cuff walls of the grooves are a different thickness than the cuff walls of the ridges.
Advantages of the invention may become apparent upon reading the following detailed description and upon reference to the drawings in which:
One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, not all features of an actual implementation are described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.
It is desirable to provide a medical balloon such as an endotracheal cuff or other medical device that may substantially seal the passage in which the cuff is inserted without forming leak paths through which secretions may pass into the lungs. In accordance with some aspects of the present technique, a medical balloon with grooved regions is provided that is adapted to be used with an endotracheal tube or device.
The grooved balloon cuffs provided herein may provide advantages over a typical cuff. A typical inflatable cuff generally assumes a cylindrical or barrel shape when inflated. Thus, a generally cylindrical cuff has a constant diameter along most of its length when fully inflated. This diameter is typically larger than the size of the tracheal passage. Therefore, when a typical cylindrical cuff is inserted into a patient's trachea and inflated, the cuff walls of the cylinder are unable to inflate to their maximum diameter and may fold in on themselves in order to fit in the trachea, which causes wrinkles and leak paths to form.
A grooved cuff shape may provide an improved seal against a patient's passage. The grooved shape of the cuffs as provided herein results in variable inflated cuff diameters along the axis of the patient's passage. By creating a variable diameter cuff profile, the grooves may interrupt the formation of wrinkles or leak paths in the wider ridges that surround the grooves and may thus improve cuff sealing. Further, the grooves may create a shape that complements the naturally grooved contours of a patient's tracheal walls, allowing the cuff to interact with the tracheal walls more closely to prevent leaks. Additionally, the grooved cuffs may include a tapered shape that may improve cuff sealing through a larger variation in inflated cuff diameters along the length of the cuff. The larger variation may increase the likelihood of a substantial match of one of those diameters to the patient's tracheal diameter. Where the cuff diameter is substantially equal to the tracheal diameter, there is a reduced possibility of wrinkles forming in the cuff. Grooved cuff designs also allow for sealing at lower pressures reducing the risk of patient discomfort during ventilation.
Grooved medical cuffs as provided herein may be used in conjunction with any suitable medical device. In certain embodiments, the grooved cuffs as provided herein may be used in conjunction with a catheter, a stent, a feeding tube, an intravenous tube, an endotracheal tube, a tracheostomy tube, a circuit, an airway accessory, a connector, an adapter, a filter, a humidifier, a nebulizer, or a prosthetic, in various embodiments.
An example of a grooved inflatable cuff used in conjunction with a medical device is a cuffed endotracheal tube 10, depicted in
The grooves 15 and ridges 14 may be characterized by their fully inflated diameters. It should be understood that groove and ridge cuff diameters may be measured when the cuff is fully inflated along an axis that is substantially orthogonal to the axis of the endotracheal tube. A cuff diameter may be measured from cuff wall to cuff wall, either exterior wall to exterior wall or interior wall to interior wall. In certain embodiments, the ridges 14 may have the diameter of an average tracheal diameter or greater. It should be understood that an average trachea size may be an adult male or female average size that is based on height and weight, or a child average size. For example, an adult trachea may range in size from 14 mm to 27 mm, with the average being around 20 mm. The tapered section may include balloon wall diameters between 20 mm and 8 mm when the balloon cuff is fully inflated, which may be appropriate for pediatric size cuffs. In specific embodiments, the grooves 15 may have a diameter that is 95% of the ridge diameter or less In a specific embodiment, it is envisioned that the grooves 15 in general may be closer in size to the tracheal diameter, while the ridges 14 that surround the grooves 15 may be about 1.2× or larger than the tracheal diameter.
The grooves 15 and ridges 14 may also be characterized by the length of each individual groove 15 or ridge 14 along the axis of the tube 16 or the patient's trachea when the cuff is inflated. For example, the grooves 15 and ridges 14 may be at least 1 mm long in one embodiment. In a specific embodiment, the grooves 15 and ridges 14 may be between 1 mm-10 mm along the axis of the tube 16. The grooves 15 and ridges 14 may also be characterized in their total length along the cuff. In certain embodiments, the grooves 15 and ridges 14 are disposed along at least 30% or 10-95% of the total length of the cuff 12 along the axis of the tube 16.
The grooves 15 and ridges 14 may also be characterized by their shape. It is envisioned that the grooves 15 and ridges 14 are substantially annular, which may include partially annular shapes, such as semi-annular or demi-annular shapes. Further, in certain embodiments, the annular grooves 15 and ridges 14 may be disposed slightly off-axis from an axis orthogonal to the tube 16, such as at an angle 5 to 15 degrees off-axis (see
The grooved cuff 12 may be formed from materials having suitable mechanical properties (such as puncture resistance, pin hole resistance, tensile strength), chemical properties (such as forming a suitable bond to the tube 16), and biocompatibility. In one embodiment, the walls of the inflatable cuff 12 are made of a polyurethane having suitable mechanical and chemical properties. An example of a suitable polyurethane is Dow Pellethane® 2363-90A. In another embodiment, the walls of the inflatable cuff 12 are made of a suitable polyvinyl chloride (PVC). Other suitable materials include polypropylene, polyethylene teraphthalate (PETP), low-density polyethylene (LDPE), silicone, neoprene, polyisoprene, or polyurethane (PU)
As depicted in
A grooved cuff 12 may have an irregular pitch, as depicted in
In certain embodiment, a grooved cuff may assume a tapered configuration, as depicted in
The tapered region 21 may be characterized by the cuff diameters at both ends of the taper. For example, the tapered shape may be described by providing the cuff diameter at the widest point of the taper as well as the cuff diameter at a narrower point. It should be understood that cuff diameters may be measured when the cuff is fully inflated along an axis that is substantially orthogonal to the axis of the endotracheal tube. A cuff diameter may be measured from cuff wall to cuff wall, either exterior wall to exterior wall or interior wall to interior wall. In specific embodiments, the tapered region may narrow from a widest cuff diameter of 30 mm to a narrower diameter of 16.5 mm or smaller. It is envisioned that a cuff may be deigned to accommodate a wide variety of tracheal sizes along a single taper. Thus, a further advantage of a tapered cuff may be its adaptability to patients of a variety of sizes. In one embodiment, certain smaller diameters at the narrow end of the cuff taper are associated with increased sealing performance. For example, certain smaller diameters at the narrow end may maintain the sealing band of the cuff around the trachea even though the tube itself may not be centered in the trachea. Due to the curvature typically built into tracheal tubes for ease of insertion and patient comfort, the tube does not necessarily stay centered in the trachea. By having smaller diameters at the narrow end, it is possible to maintain the benefits of the tapered shape even when the tube is not symmetrically located within the trachea. Thus, in certain embodiments it may be desirable to have cuff diameters less than 16.5 mm or less than 15.24 mm at the narrow end of the cuff.
In other embodiments, the tapered region 21 of the tapered cuff may be characterized by the slope or angle of the taper, which is the included angle of the tapering cuff wall and the axis of an attached endotracheal tube. For example, the angle of the taper may include a tapering angle of at least 15 degrees, at least 20 degrees, or at least 25 degrees. In a specific embodiment, the angle of the taper may be between 17 and 18 degrees. Providing tapering angles greater than 15 degrees generally indicates a greater variance between the widest point and the narrower point of the taper. Further, the tapered region of the tapered cuff may be characterized in certain embodiments by the rate of tapering from the widest point of the taper to a narrower point. A cuff may exhibit a continuous rate of tapering, or a linear tapering, from a wider diameter to a narrower diameter. In other embodiments, the taper may have a nonlinear rate of tapering. For example, it may be advantageous to provide stepwise tapering along the cuff, whereby a certain cuff diameter is maintained for 5-10 mm along the length of the taper. Additionally, a taper may be characterized by its length along the axis of an endotracheal tube. For example, a taper may be along at least 30%, at least 40%, at least 50%, at least 75%, or at least 95% of the length of the cuff along a specific axis.
In other embodiments, a cuff 12 may assume a variety of tapered shapes when inflated. For example, referring now to
The grooved cuffs as provided herein may be manufactured by a number of techniques, including blow molding, stretch blow molding, extrusion, injection molding, dip molding, casting, or any other suitable technique. The grooved cuffs 12 as provided herein may include cuff walls with constant or varying wall thicknesses along the length of the cuffs. Cuff wall thickness may vary from the widest part of the taper to the narrowest part of the taper. In certain embodiments, it is advantageous to specify cuff wall thickness variation because certain cuff wall thicknesses may be associated with a reduction in wrinkling. In certain embodiments, it may be advantageous to provide a cuff whereby the cuff walls of the grooves are relatively thinner than the cuff walls of the ridges. For example, the cuff walls in the ridges may be at least 1.2×, 1.5×, or 2× thicker than the cuff walls at the narrowest diameter portion of the groove. Such an embodiment may be advantageous because the grooved regions may be more likely to form wrinkle-free bands against the tracheal walls. In certain embodiments, it is contemplated that the cuff walls in the tapered region of the cuff are less than 60 microns in thickness. In another embodiment, the cuff walls are between 10 microns and 3 millimeters in thickness. In specific embodiments, the cuff walls vary along the length of the cuff from between 10 microns to 140 microns in thickness, from between 20 microns to 60 microns in thickness, and from between 30 microns to 50 microns in thickness.
This thickness variation may be accomplished in a number of ways. For example, in one embodiment, the tapered cuffs may be manufactured by an extrusion blow molding process. In this process, a core or mandrel of the extruder has apertures to admit a gas such as pressurized air or an inert gas like nitrogen, into the medical device in the neighborhood of the cuff. After a length of medical device has been extruded, a mold clamps the medical device around the mandrel. As gas is admitted to the cuff area through the mandrel, the cuff expands against the mold. In the alternative, the cuff wall may be expanded in a second discrete expansion process following an extrusion or molding process, such as with a shuttle blow molding process. After initial extrusion, the extruded cuff will have a generally tubular shape with a substantially uniform wall thickness. This tubular shape may then be blown into the tapered shape. This process results in the area of the cuff with larger diameters having thinner walls because the same amount of material is stretched over a larger area. In an alternate embodiment, the wall thickness variation along the length of the taper may be specified in the blow molding process by using a programmable parasin on the extruder. A parasin may also be used to specify a constant wall thickness. A programmable parasin allows the wall thickness being extruded to be controlled as a function of length. Therefore, the extruded section may have walls of constant or varying thickness. This extruded section may then be blowmolded as described. Other cuff shapes and designs are discussed in the U.S. patent applications titled “ENDOTRACHEAL CUFF AND TECHNIQUE FOR USING THE SAME” to Donald S. Nelson and Dhairya Mehta filed on Jun. 22, 2006, “ENDOTRACHEAL CUFF AND TECHNIQUE FOR USING THE SAME” to Donald S. Nelson and Dhairya Mehta filed on Jun. 22, 2006, and the U.S. patent application titled “THIN CUFF FOR USE WITH MEDICAL TUBING AND APPARATUS FOR MAKING THE SAME” to Joel Colburn and Roger Caluya filed on Jun. 22, 2006, which are hereby incorporated by reference in their entirety.
In certain embodiments, it may be desirable for the grooved cuff 12 to include an antimicrobial surface to prevent the adhesion and propagation of biofilms. The cuff 12 may be formed from hydrophobic polymer with an outer antimicrobial layer that includes a hydrophilic polymer and an antimicrobial compound disposed on an outer surface of the cuff wall. The antimicrobial layer may include an antimicrobial metal, such as copper, silver, or gold. In several exemplary embodiments, the metal may be elemental silver, powdered silver, silver ions (Ag+), or a silver bearing material like silver oxide (AgO). The hydrophilic layer may thus be an antimicrobial (AM) layer. In this way the colonization-inhibiting properties of the hydrophilic surface can be reinforced by anti-microbial properties.
It may be desirable for the metal to be released over time, while the medical device is in use. In one embodiment, therefore, a silver-bearing time-release material may be a phosphorus-based glass material that dissolves in water at a rate that may be a function of its particular formulation. The glass may also contain trace amounts of other elements, such as calcium oxide (CaO). The rate at which silver is released may further be a function of the rate at which the phosphorus-based glass material dissolves in water. The silver, or the phosphorus-based glass material, or both, may be powdered. The release of silver over time, which is defined as the elution rate and is measured in micrograms/cm2/day, may thus be tailored to the specific needs of the application by specifying the formulation of the phosphorus-based glass material. In one embodiment, the silver bearing material may be made up of about 5-10% by weight, e.g. about 7.5% phosphorus-based glass by weight. Such a material is available from Giltech Limited, 12 North Harbour Industrial Estate, Ayr, Scotland, Great Britain KA8 8BN. In one embodiment, the elution rate should be up to about 0.01 micrograms/cm2/day. In another embodiment, the elution rate may be between about 0.01 and 1.0 micrograms/cm2/day. In another embodiment, the elution rate may be about 0.4 micrograms/cm2/day.
In other embodiments, bioactive pharmaceutical agents such as a bronchodilator, an anti-inflammatory agent, or a local anesthetic may be substantially dispersed in a phosphorus-based glass material within a hydrophilic layer. Such bioactive pharmaceutical agents may be delivered to and absorbed by adjacent tissues in substantially the same manner as silver. Regulation and control of dosage, elution rate, and thickness in substantially the same manner as silver may also provide a beneficial pharmacologic or therapeutic action.
A hydrophilic coating may be applied to the surface of a medical device by, e.g., extruding, molding, dipping, spraying, washing, or painting the hydrophilic coating on the surface. In one embodiment, a medical device may be formed by extruding a wall of hydrophobic material along with one or more layers of an antimicrobial material. In another embodiment, a medical device may be formed by molding a wall of hydrophobic material along with one or more layers of an antimicrobial material. The antimicrobial layer may be formed on an inner or an outer surface of the medical device wall. The antimicrobial layer may be comprised of, e.g. polyurethane, such as a medical grade hydrophilic thermoplastic polyurethane into which has been substantially dispersed a silver bearing phosphorus-based glass material. In one embodiment, the antimicrobial layer may be within a range of about 0.002 mm-2.5 mm in thickness, or about 0.13 mm in thickness. In another embodiment, the antimicrobial layer may be within a range of about 0.002 mm-2.5 mm in thickness. In another embodiment, the antimicrobial layer may be up to about 6.35 mm in thickness. In another embodiment, the hydrophobic polymer, hydrophilic polymer and the antimicrobial compound may be compounded together and extruded to form a cuff wall 24.
The tracheal cuffs 12 of the present techniques may be incorporated into systems that facilitate positive pressure ventilation of a patient, such as a ventilator. Such systems may typically include connective tubing, a gas source, a monitor, and/or a controller. The controller may be a digital controller, a computer, an electromechanical programmable controller, or any other control system.
Typically, endotracheal cuffs are inflated within a patient's trachea such that the intra cuff pressure is approximately 20-25 cm H2O. Endotracheal cuffs utilizing inflation pressures significantly greater 25 cm H2O may be referred to as high-pressure cuffs, while cuffs that are able to effectively seal the trachea at pressures less than 25 cm H2O may be considered low-pressure cuffs. In certain embodiment, intra cuff inflation pressures of 10-30 cm H2O may be used with the grooved cuffs of the present techniques.
While the invention may be susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and have been described in detail herein. However, it should be understood that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the following appended claims.
Number | Name | Date | Kind |
---|---|---|---|
2927584 | Wallace | Mar 1960 | A |
3769983 | Merav | Nov 1973 | A |
3810474 | Cross | May 1974 | A |
3822238 | Blair et al. | Jul 1974 | A |
3913565 | Kawahara | Oct 1975 | A |
3971385 | Corbett | Jul 1976 | A |
3975350 | Hudgin et al. | Aug 1976 | A |
3995643 | Merav | Dec 1976 | A |
4022217 | Rowean | May 1977 | A |
4130617 | Wallace | Dec 1978 | A |
4230108 | Young | Oct 1980 | A |
4231365 | Scarberry | Nov 1980 | A |
4235239 | Elam | Nov 1980 | A |
4340046 | Cox | Jul 1982 | A |
4569344 | Palmer | Feb 1986 | A |
4638539 | Palmer | Jan 1987 | A |
4649913 | Watson | Mar 1987 | A |
4696296 | Palmer | Sep 1987 | A |
4700700 | Eliachar | Oct 1987 | A |
4791920 | Fauza | Dec 1988 | A |
4825859 | Lambert | May 1989 | A |
4825861 | Koss | May 1989 | A |
4834726 | Lambert | May 1989 | A |
4836199 | Palmer | Jun 1989 | A |
4838255 | Lambert | Jun 1989 | A |
4850348 | Pell et al. | Jul 1989 | A |
4856510 | Kowalewski | Aug 1989 | A |
4867153 | Lorenzen et al. | Sep 1989 | A |
4872579 | Palmer | Oct 1989 | A |
4886059 | Weber | Dec 1989 | A |
4927412 | Menasche | May 1990 | A |
4938741 | Lambert | Jul 1990 | A |
4963313 | Noddin et al. | Oct 1990 | A |
4967743 | Lambert | Nov 1990 | A |
4979505 | Cox | Dec 1990 | A |
5019042 | Sahota | May 1991 | A |
5020534 | Pell et al. | Jun 1991 | A |
5021045 | Buckberg et al. | Jun 1991 | A |
5025806 | Palmer et al. | Jun 1991 | A |
5029580 | Radford et al. | Jul 1991 | A |
5033466 | Weymuller, Jr. | Jul 1991 | A |
5041125 | Montano, Jr. | Aug 1991 | A |
5060646 | Page | Oct 1991 | A |
5065754 | Jensen | Nov 1991 | A |
5074840 | Yoon | Dec 1991 | A |
5076268 | Weber | Dec 1991 | A |
5098379 | Conway et al. | Mar 1992 | A |
5103816 | Kirschbaum et al. | Apr 1992 | A |
5107829 | Lambert | Apr 1992 | A |
5120322 | Davis et al. | Jun 1992 | A |
5122122 | Allgood | Jun 1992 | A |
5133345 | Lambert | Jul 1992 | A |
5135516 | Sahatjian et al. | Aug 1992 | A |
5137671 | Conway et al. | Aug 1992 | A |
5158569 | Strickland et al. | Oct 1992 | A |
5165420 | Strickland | Nov 1992 | A |
5176638 | Don Michael | Jan 1993 | A |
5190810 | Kirschbaum et al. | Mar 1993 | A |
5199427 | Strickland | Apr 1993 | A |
5201310 | Turnbull et al. | Apr 1993 | A |
5207643 | Davis | May 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5218957 | Strickland | Jun 1993 | A |
5230332 | Strickland | Jul 1993 | A |
5233979 | Strickland | Aug 1993 | A |
5246012 | Strickland | Sep 1993 | A |
5250070 | Parodi | Oct 1993 | A |
5251619 | Lee | Oct 1993 | A |
5261896 | Conway et al. | Nov 1993 | A |
5263478 | Davis | Nov 1993 | A |
5269770 | Conway et al. | Dec 1993 | A |
5277177 | Page et al. | Jan 1994 | A |
5285777 | Beckwith | Feb 1994 | A |
5290585 | Elton | Mar 1994 | A |
5304121 | Sahatjian | Apr 1994 | A |
5331027 | Whitbourne | Jul 1994 | A |
5360402 | Conway et al. | Nov 1994 | A |
5370656 | Shevel | Dec 1994 | A |
5370899 | Conway et al. | Dec 1994 | A |
5374261 | Yoon | Dec 1994 | A |
5392787 | Yoon | Feb 1995 | A |
5397302 | Weaver et al. | Mar 1995 | A |
5407423 | Yoon | Apr 1995 | A |
5417671 | Jackson | May 1995 | A |
5423745 | Todd et al. | Jun 1995 | A |
5439457 | Yoon | Aug 1995 | A |
5443063 | Greenberg | Aug 1995 | A |
5447505 | Valentine et al. | Sep 1995 | A |
5451204 | Yoon | Sep 1995 | A |
5466231 | Cercone et al. | Nov 1995 | A |
5469864 | Rosenblatt | Nov 1995 | A |
5482740 | Conway et al. | Jan 1996 | A |
5484426 | Yoon | Jan 1996 | A |
5487730 | Maracadis et al. | Jan 1996 | A |
5494029 | Lane et al. | Feb 1996 | A |
5501669 | Conway et al. | Mar 1996 | A |
5507284 | Daneshvar | Apr 1996 | A |
5509899 | Fan et al. | Apr 1996 | A |
5524642 | Rosenblatt | Jun 1996 | A |
5545132 | Fagan et al. | Aug 1996 | A |
5556391 | Cercone et al. | Sep 1996 | A |
5593718 | Conway et al. | Jan 1997 | A |
5599292 | Yoon | Feb 1997 | A |
5599299 | Weaver et al. | Feb 1997 | A |
5599321 | Conway et al. | Feb 1997 | A |
5611336 | Page et al. | Mar 1997 | A |
5613950 | Yoon | Mar 1997 | A |
5649902 | Yoon | Jul 1997 | A |
5653229 | Greenberg | Aug 1997 | A |
5670111 | Conway et al. | Sep 1997 | A |
5674192 | Sahatjian et al. | Oct 1997 | A |
5693014 | Abele et al. | Dec 1997 | A |
5694922 | Palmer | Dec 1997 | A |
5697365 | Pell | Dec 1997 | A |
5700239 | Yoon | Dec 1997 | A |
5715815 | Lorenzen et al. | Feb 1998 | A |
5720726 | Marcadis et al. | Feb 1998 | A |
5722931 | Heaven | Mar 1998 | A |
5730123 | Lorenzen | Mar 1998 | A |
5733252 | Yoon | Mar 1998 | A |
5735271 | Lorenzen et al. | Apr 1998 | A |
5765559 | Kim | Jun 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5810786 | Jackson et al. | Sep 1998 | A |
5819733 | Bertram | Oct 1998 | A |
5827215 | Yoon | Oct 1998 | A |
5843017 | Yoon | Dec 1998 | A |
5843028 | Weaver et al. | Dec 1998 | A |
5843060 | Cercone | Dec 1998 | A |
5843089 | Sahatjian et al. | Dec 1998 | A |
5868719 | Tsukernik | Feb 1999 | A |
5908406 | Ostapchenko | Jun 1999 | A |
5951597 | Westlund et al. | Sep 1999 | A |
5954706 | Sahatjian | Sep 1999 | A |
5954740 | Ravenscroft et al. | Sep 1999 | A |
5971954 | Conway et al. | Oct 1999 | A |
5976072 | Greenberg | Nov 1999 | A |
5997503 | Willis et al. | Dec 1999 | A |
5997546 | Foster et al. | Dec 1999 | A |
6010480 | Abele et al. | Jan 2000 | A |
6012451 | Palmer | Jan 2000 | A |
6048332 | Duffy et al. | Apr 2000 | A |
6110192 | Ravenscroft et al. | Aug 2000 | A |
6129547 | Cise | Oct 2000 | A |
6152136 | Pagan | Nov 2000 | A |
6169123 | Cercone | Jan 2001 | B1 |
6210364 | Anderson et al. | Apr 2001 | B1 |
6214895 | Cercone | Apr 2001 | B1 |
6227200 | Crump et al. | May 2001 | B1 |
6240321 | Janke et al. | May 2001 | B1 |
6248088 | Yoon | Jun 2001 | B1 |
6264631 | Willis et al. | Jul 2001 | B1 |
6264633 | Knorig | Jul 2001 | B1 |
6277089 | Yoon | Aug 2001 | B1 |
6312421 | Boock | Nov 2001 | B1 |
6322586 | Monroe et al. | Nov 2001 | B1 |
6364856 | Ding et al. | Apr 2002 | B1 |
6378521 | Van Den Berg | Apr 2002 | B1 |
6394093 | Lethi | May 2002 | B1 |
6395012 | Yoon et al. | May 2002 | B1 |
6398266 | Crump | Jun 2002 | B1 |
6409716 | Sahatjian et al. | Jun 2002 | B1 |
6481436 | Neame | Nov 2002 | B1 |
6494203 | Palmer | Dec 2002 | B1 |
6524274 | Rosenthal et al. | Feb 2003 | B1 |
6526977 | Göbel | Mar 2003 | B1 |
6543451 | Crump et al. | Apr 2003 | B1 |
6551272 | Göbel | Apr 2003 | B2 |
6572813 | Zhang et al. | Jun 2003 | B1 |
6584970 | Crump et al. | Jul 2003 | B1 |
6588425 | Rouns et al. | Jul 2003 | B2 |
6588427 | Carlsen et al. | Jul 2003 | B1 |
6602218 | Yoon | Aug 2003 | B2 |
6602219 | Madsen et al. | Aug 2003 | B2 |
6609520 | Carlsen et al. | Aug 2003 | B1 |
6612304 | Cise et al. | Sep 2003 | B1 |
6612305 | Fauza | Sep 2003 | B2 |
6613025 | Palasis | Sep 2003 | B1 |
6615835 | Cise et al. | Sep 2003 | B1 |
6620128 | Simhambhatla | Sep 2003 | B1 |
6623450 | Dutta | Sep 2003 | B1 |
6629530 | Cise | Oct 2003 | B2 |
6632091 | Cise et al. | Oct 2003 | B1 |
6651664 | Lomholt | Nov 2003 | B1 |
6688306 | Cise et al. | Feb 2004 | B1 |
6698424 | Madsen et al. | Mar 2004 | B2 |
6705320 | Anderson | Mar 2004 | B1 |
6722368 | Shaikh | Apr 2004 | B1 |
6726696 | Houser et al. | Apr 2004 | B1 |
6745773 | Gobel | Jun 2004 | B1 |
6767340 | Willis et al. | Jul 2004 | B2 |
6769430 | Carlsen et al. | Aug 2004 | B1 |
6770066 | Weaver et al. | Aug 2004 | B1 |
6786876 | Cox | Sep 2004 | B2 |
6790221 | Monroe et al. | Sep 2004 | B2 |
6796309 | Nash et al. | Sep 2004 | B2 |
6802317 | Gobel | Oct 2004 | B2 |
6805125 | Crump et al. | Oct 2004 | B1 |
6808521 | McMichael | Oct 2004 | B1 |
6814730 | Li | Nov 2004 | B2 |
6890339 | Sahatjian et al. | May 2005 | B2 |
6908449 | Willis et al. | Jun 2005 | B2 |
6916307 | Willis et al. | Jul 2005 | B2 |
6923786 | Rouns et al. | Aug 2005 | B2 |
6997909 | Goldberg | Feb 2006 | B2 |
7040321 | Gobel | May 2006 | B2 |
7040322 | Fortuna | May 2006 | B2 |
7066905 | Squire et al. | Jun 2006 | B2 |
7147252 | Teuscher et al. | Dec 2006 | B2 |
7258120 | Carlsen et al. | Aug 2007 | B2 |
7360540 | Brain et al. | Apr 2008 | B2 |
20010016724 | Davis et al. | Aug 2001 | A1 |
20020032407 | Willis et al. | Mar 2002 | A1 |
20020077603 | Willis et al. | Jun 2002 | A1 |
20020077604 | Willis et al. | Jun 2002 | A1 |
20020078960 | Cise | Jun 2002 | A1 |
20020078963 | Rouns et al. | Jun 2002 | A1 |
20020082552 | Ding et al. | Jun 2002 | A1 |
20020091375 | Sahatjian et al. | Jul 2002 | A1 |
20020193753 | Rouns et al. | Dec 2002 | A1 |
20020195110 | Watton | Dec 2002 | A1 |
20030000526 | Gobel | Jan 2003 | A1 |
20030066532 | Gobel | Apr 2003 | A1 |
20030069620 | Li | Apr 2003 | A1 |
20030111077 | Hooser et al. | Jun 2003 | A1 |
20030116162 | Madsen et al. | Jun 2003 | A1 |
20030116963 | Teuscher et al. | Jun 2003 | A1 |
20030225369 | McMichael et al. | Dec 2003 | A1 |
20030225392 | McMichael et al. | Dec 2003 | A1 |
20030225393 | McMichael et al. | Dec 2003 | A1 |
20040024363 | Goldberg | Feb 2004 | A1 |
20040079376 | Melker | Apr 2004 | A1 |
20040092870 | Squire et al. | May 2004 | A1 |
20040106899 | McMichael et al. | Jun 2004 | A1 |
20040106900 | Triebes et al. | Jun 2004 | A1 |
20040106901 | Letson et al. | Jun 2004 | A1 |
20040116898 | Hawk | Jun 2004 | A1 |
20040154623 | Schaeffer et al. | Aug 2004 | A1 |
20040193100 | Van Hooser et al. | Sep 2004 | A1 |
20040193101 | Van Hooser et al. | Sep 2004 | A1 |
20040215142 | Matheis et al. | Oct 2004 | A1 |
20040220534 | Martens et al. | Nov 2004 | A1 |
20040221853 | Miller | Nov 2004 | A1 |
20040255951 | Grey | Dec 2004 | A1 |
20040255952 | Carlsen et al. | Dec 2004 | A1 |
20050004560 | Cox | Jan 2005 | A1 |
20050033267 | Decaria | Feb 2005 | A1 |
20050033268 | Decaria | Feb 2005 | A1 |
20050033269 | Decaria | Feb 2005 | A1 |
20050038381 | McMichael | Feb 2005 | A1 |
20050065468 | Goebel | Mar 2005 | A1 |
20050124932 | Foster et al. | Jun 2005 | A1 |
20050124935 | McMichael | Jun 2005 | A1 |
20050137619 | Schewe et al. | Jun 2005 | A1 |
20050166924 | Thomas et al. | Aug 2005 | A1 |
Number | Date | Country |
---|---|---|
2353007 | Jun 2000 | CA |
2353007 | Jun 2000 | CA |
4334037 | Apr 1995 | DE |
19500550 | Jul 1996 | DE |
19855521 | Jun 2000 | DE |
19855521 | Jun 2000 | DE |
0884061 | Jun 1998 | EP |
0884061 | Dec 1998 | EP |
1267981 | Apr 2000 | EP |
1005877 | Jun 2000 | EP |
1135184 | Jun 2000 | EP |
1402255 | Aug 1975 | GB |
2168256 | Jun 1986 | GB |
WO 9522367 | Aug 1995 | WO |
WO 0027461 | May 2000 | WO |
WO 0032262 | Jun 2000 | WO |
WO 0032263 | Jun 2000 | WO |
WO 0197890 | Dec 2001 | WO |
WO 03045487 | Jun 2003 | WO |
WO 2004067262 | Aug 2004 | WO |
WO 2004101046 | Nov 2004 | WO |
WO 2006023486 | Mar 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20080000482 A1 | Jan 2008 | US |